Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
H Mizuta, K Okada, M Araki, J Adachi… - Nature …, 2021 - nature.com
ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients,
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
R Katayama, L Friboulet, S Koike, EL Lockerman… - Clinical cancer …, 2014 - AACR
Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a standard
therapy for patients with ALK-rearranged non–small cell lung cancer (NSCLC). Several next …
therapy for patients with ALK-rearranged non–small cell lung cancer (NSCLC). Several next …
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and …
SHI Ou, J Greenbowe, ZU Khan, MC Azada, JS Ross… - Lung cancer, 2015 - Elsevier
Objectives Acquired resistance mutations to anaplastic lymphoma kinase (ALK) inhibitors
such as crizotinib and alectinib have been documented in non-small cell lung cancer …
such as crizotinib and alectinib have been documented in non-small cell lung cancer …
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
R Katayama, AT Shaw, TM Khan… - Science translational …, 2012 - science.org
Most anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancers (NSCLCs)
are highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However …
are highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However …
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
N Yamaguchi, AR Lucena-Araujo, S Nakayama… - Lung cancer, 2014 - Elsevier
Introduction The multitargeted tyrosine kinase inhibitor (TKI) crizotinib is active against ALK
translocated non-small-cell lung cancer (NSCLC); however acquired resistance invariably …
translocated non-small-cell lung cancer (NSCLC); however acquired resistance invariably …
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
RC Doebele, AB Pilling, DL Aisner, TG Kutateladze… - Clinical cancer …, 2012 - AACR
Purpose: Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often
manifest dramatic responses to crizotinib, a small-molecule ALK inhibitor. Unfortunately, not …
manifest dramatic responses to crizotinib, a small-molecule ALK inhibitor. Unfortunately, not …
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Advanced, anaplastic lymphoma kinase (ALK)–positive lung cancer is currently treated with
the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK …
the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK …
Identification of a novel ALK G1123S mutation in a patient with ALK-rearranged non–small-cell lung cancer exhibiting resistance to ceritinib
G Toyokawa, E Inamasu, S Shimamatsu… - Journal of Thoracic …, 2015 - jto.org
1. Ignatius Ou SH, Azada M, Hsiang DJ, et al. Next-generation sequencing reveals a Novel
NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level …
NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level …
Non–small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases
Crizotinib is the standard of care for advanced non–small cell lung cancer (NSCLC) patients
harboring the anaplastic lymphoma kinase (ALK) fusion gene, but resistance invariably …
harboring the anaplastic lymphoma kinase (ALK) fusion gene, but resistance invariably …
The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer
Non–small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene
rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) …
rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) …
相关搜索
- alk inhibitors lung cancer
- alk inhibitor crizotinib resistance
- lung cancers crizotinib resistance
- alk mutations acquired resistance
- alk inhibitors mechanisms of resistance
- alk inhibitor acquired resistance
- crizotinib in alk lung cancer
- dual alk lung cancer
- acquired resistance lung cancer
- crizotinib in alk acquired resistance
- dual alk acquired resistance